Selective estrogen receptor modulators (SERMs): New alternatives for osteoarthritis?

被引：28

作者：

Lugo, L. ^{[1
]}

Villalvilla, A. ^{[1
]}

Largo, R. ^{[1
]}

Herrero-Beaumont, G. ^{[1
]}

Roman-Bias, J. A. ^{[1
]}

机构：

[1] IIS Fdn Jimenez Diaz Univ Autonoma, Rheumatol Serv, Bone & Joint Res Unit, Madrid, Spain

来源：

MATURITAS | 2014年 / 77卷 / 04期

关键词：

Hormone therapy; Estrogen receptors; Osteoarthritis; Selective estrogen receptor modulators; PERIARTICULAR TIBIAL OSTEOPHYTES; REPLACEMENT-THERAPY; OVARIECTOMIZED RATS; KNEE OSTEOARTHRITIS; HORMONE-REPLACEMENT; SUBCHONDRAL BONE; MURINE MODEL; CARTILAGE; TURNOVER; WOMEN;

D O I：

10.1016/j.maturitas.2014.01.016

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

The dramatic rise in the prevalence rate of osteoarthritis (OA) after the menopause and the presence of estrogen receptors in joint tissues suggest that estrogen may help protect against the development of OA. Trials of estrogen therapy have produced inconclusive results, however, partly because of flaws in study design and partly because of the complexity of the mechanisms underlying estrogen's effects on joint tissues. Initial studies of the use of selective estrogen receptor modulators (SERMs) have reported beneficial effects in OA. These agents may exert both a direct effect upon joint cartilage and indirect effects on subchondral bone, synovium, muscle, tendons and ligaments. SERMs may be particularly beneficial for postmenopausal patients with osteoporotic OA, a phenotype defined by decreased bone density, associated with high remodeling in subchondral bone. More research is needed, though, before SERMs can become a therapeutic option for OA. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

引用

页码：380 / 384

页数：5

共 50 条

[21] Unusual behavior of organometallic SERMs (selective estrogen receptor modulators).
Jaouen, G
Top, S
Vessieres, A
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U695 - U695
[22] Specific estrogen receptor modulators (SERMs)
Trémollières, F
Lopes, P
PRESSE MEDICALE, 2002, 31 (28): : 1323 - 1328
[23] Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance
Lewis, JS
Jordan, VC
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2005, 591 (1-2) : 247 - 263
[24] Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
Sambrook, P
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2005, 19 (06): : 975 - 981
[25] The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice
Maximov, Philipp Y.
Lee, Theresa M.
Jordan, V. Craig
CURRENT CLINICAL PHARMACOLOGY, 2013, 8 (02): : 135 - 155
[26] Bioactivation of selective estrogen receptor modulators (SERMs) to reactive quinoids.
Bolton, JL
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (11) : 2769S - 2770S
[27] Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention
Zujewski, J
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2002, 39 (2-3) : 264 - 270
[28] Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention
Park, WC
Jordan, VC
TRENDS IN MOLECULAR MEDICINE, 2002, 8 (02) : 82 - 88
[29] Selective estrogen receptor modulators (SERMs) suppress cartilage turnover.
Christgau, S
Tankó, LB
Cloos, PAC
Christiansen, C
ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S289 - S289
[30] Selective estrogen receptor modulators (SERMs): Effects on multiple organ systems
Agnusdei, D
Lori, N
CURRENT MEDICINAL CHEMISTRY, 2000, 7 (05) : 577 - 584

← 1 2 3 4 5 →